ストックスクリーナーアプリを入手
64.80
3.37%
-2.26
アフターアワーズ：
64.35
-0.45
-0.69%
前日終値:
$67.06
開ける：
$67.08
24時間の取引高:
1.40M
Relative Volume:
0.98
時価総額：
$4.48B
収益：
-
当期純損益:
$-100.44M
株価収益率:
-29.19
EPS:
-2.22
ネットキャッシュフロー:
$-105.32M
1週間 パフォーマンス:
-7.40%
1か月 パフォーマンス:
+75.99%
6か月 パフォーマンス:
+198.89%
1年 パフォーマンス:
+107.36%
1日の値動き範囲:
$64.36
$68.56
1週間の範囲:
$64.36
$72.39
52週間の値動き範囲:
$13.22
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
名前
Structure Therapeutics Inc Adr
セクター
電話
(650) 457-1978
住所
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
GPCR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
64.80 | 4.64B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-02 | 開始されました | Citigroup | Buy |
| 2025-02-28 | 開始されました | William Blair | Outperform |
| 2025-01-08 | 開始されました | Stifel | Buy |
| 2024-12-04 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-05-21 | 開始されました | JP Morgan | Overweight |
| 2024-04-09 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-07-27 | 開始されました | Piper Sandler | Overweight |
| 2023-05-25 | 再開されました | Jefferies | Buy |
| 2023-02-28 | 開始されました | BMO Capital Markets | Outperform |
| 2023-02-28 | 開始されました | Guggenheim | Buy |
| 2023-02-28 | 開始されました | Jefferies | Buy |
| 2023-02-28 | 開始されました | SVB Securities | Outperform |
すべてを表示
Structure Therapeutics Inc Adr (GPCR) 最新ニュース
Structure Therapeutics (NASDAQ:GPCR) Price Target Raised to $120.00 - Defense World
Mid Cap Stocks To Watch TodayDecember 8th - MarketBeat
Bellevue Group AG Acquires 126,812 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Birchview Capital LP Buys Shares of 36,000 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics stock price target raised to $120 by Citizens - Investing.com South Africa
Structure Therapeutics (NASDAQ:GPCR) Raised to Hold at Wall Street Zen - MarketBeat
Structure Therapeutics Inc. (GPCR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Federated Hermes Inc. Decreases Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics closes $747.5 million public offering - Investing.com
Pharmaceutical Stocks To Follow TodayDecember 8th - MarketBeat
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Bought by HighVista Strategies LLC - MarketBeat
Structure Therapeutics announces $650 million public offering - MSN
Structure Therapeutics Announces $650 Million Public Offering - TipRanks
Structure Therapeutics’ Leap: What’s Sparking the Surge? - StocksToTrade
Structure Therapeutics Shares Surge on Promising Drug Results - TipRanks
Structure Therapeutics Inc. (GPCR) Stock: Skyrockets After Positive Obesity Trial Result - Menafn
Structure Therapeutics prices upsized $650 million public offering By Investing.com - Investing.com South Africa
Structure Therapeutics prices upsized $650 million public offering - Investing.com
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants - GlobeNewswire Inc.
Structure Therapeutics (GPCR) Hits 52-Week High on Weight Loss Treatment Trial - Finviz
Structure Therapeutics (NASDAQ:GPCR) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Discipline and Rules-Based Execution in GPCR Response - news.stocktradersdaily.com
Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook - ts2.tech
GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron - Yahoo Finance
This trade activity should not be overlooked: Structure Therapeutics Inc ADR (GPCR) - setenews.com
Structure Therapeutics stock price target raised to $130 by BMO Capital - Investing.com
Structure Therapeutics stock price target raised to $99 at Clear Street - Investing.com
Biggest Stock Gainers Today in the US (Dec. 9, 2025): Wave Life Sciences, Structure Therapeutics, Confluent and More - ts2.tech
Structure Therapeutics Stock Jumps on Trial Results for Weight-Loss Pill - The Wall Street Journal
Why Structure Therapeutics Stock Doubled and Then Some on Monday - The Globe and Mail
Structure Therapeutics stock hits 52-week high at 45.05 USD By Investing.com - Investing.com Canada
Structure Therapeutics Unveils Major Data Release Driving Market Buzz - StocksToTrade
Structure Therapeutics stock price target raised to $90 by Stifel - Investing.com
Structure Therapeutics stock falls after $500 million share offering By Investing.com - Investing.com India
Structure Therapeutics stock falls after $500 million share offering - Investing.com
Structure Therapeutics launches $500 million public offering - Investing.com
Structure Therapeutics launches $500 million public offering By Investing.com - Investing.com South Africa
Structure Therapeutics (NASDAQ: GPCR) plans $500M ADS sale with $75M option - Stock Titan
2 companies poised to capitalize on the rise of GLP-1 drugs - Morningstar Australia
Structure Therapeutics’ Potential Breakthrough: Market Awaits Data - StocksToTrade
Medical Stocks To Watch TodayDecember 8th - MarketBeat
Promising Potential of Structure Therapeutics’ Aleniglipron: A Buy Rating Based on Transformative Efficacy and Strategic Innovation - TipRanks
Positive Outlook for Structure Therapeutics: Aleniglipron Shows Promising Results in Obesity Treatment - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Hits New 1-Year HighStill a Buy? - MarketBeat
Structure Phase 2 data for aleniglipron look ‘competitive,’ says Morgan Stanley - TipRanks
Structure Therapeutics posts mid-stage weight-loss pill data in line with Eli Lilly rival - Sherwood News
Structure Therapeutics stock hits 52-week high at 45.05 USD - Investing.com
Structure Therapeutics Announces Positive Clinical Trial Results - TipRanks
Structure Therapeutics stock soars after strong weight loss data for oral drug - Investing.com UK
Structure Therapeutics Inc Adr (GPCR) 財務データ
収益
当期純利益
現金流量
EPS
0.36%
1.05%
大文字化:
|
ボリューム (24 時間):